Becton Dickinson's Q4 Revenues Rise 7 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its revenues rose 7 percent in its fiscal fourth quarter year over year.

For the three months ended Sept. 30, revenues totaled $2.10 billion, compared to $1.97 billion and beat the average analyst estimate of $2.05 billion.

By segment, BD Diagnostics' revenues increased to $680 million from $645 million, while BD Medical rose to $1.12 billion from $1.05 billion. BD Biosciences was up to $208 million from $185 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.